Literature DB >> 7687314

Site-specific differences in pp60c-src activity in human colorectal metastases.

P M Termuhlen1, S A Curley, M S Talamonti, M H Saboorian, G E Gallick.   

Abstract

The c-src proto-oncogene has been implicated in the progression of primary human colorectal carcinoma to hepatic metastasis. To determine if increased pp60c-src tyrosine kinase activity is a colon-specific phenomenon present in colorectal metastases to all sites, the pp60c-src-specific kinase activity of noncolon tumor metastases to the liver was compared to that of colorectal liver metastases. Activity of extrahepatic colon carcinoma metastases was compared to that of colorectal liver metastases as well as that of normal colonic mucosa. The specific activity of pp60c-src in multiple synchronous metastases from colon carcinoma was also examined. Tyrosine kinase activity was determined by immune complex kinase assay; protein levels were determined by immunoblotting. Specific activity was calculated for each group by dividing the total activity by protein level. Colon carcinoma metastases to the liver had significantly (P < 0.04) increased pp60c-src activity with an average 2.2-fold increase over normal mucosa. In contrast, noncolon tumor metastases to the liver showed minimal pp60c-src kinase activity. Extrahepatic colorectal metastases demonstrated significantly increased (P < 0.005) pp60c-src activity with an average 12.7-fold increase over normal mucosa. When compared to colon liver metastases, extrahepatic colorectal tumor metastases show a significant difference in activity (P < 0.05) with an average 5.7-fold increase. Examination of multiple synchronous colon carcinoma metastases confirmed these results. In summary, we conclude that (1) the activation of pp60c-src between primary tumors and metastases is specific to colon metastases, and (2) although pp60c-src activity is significantly increased in colorectal metastases, site-specific differences in the magnitude of activity are evident.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687314     DOI: 10.1006/jsre.1993.1046

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  24 in total

1.  Src tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer.

Authors:  Karthikeyani Chellappa; Lucy Jankova; Jake M Schnabl; Songqin Pan; Yann Brelivet; Caroline L-S Fung; Charles Chan; Owen F Dent; Stephen J Clarke; Graham R Robertson; Frances M Sladek
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.

Authors:  John H Strickler; Shannon McCall; Andrew B Nixon; John C Brady; Herbert Pang; Christel Rushing; Allen Cohn; Alexander Starodub; Christy Arrowood; Sherri Haley; Kellen L Meadows; Michael A Morse; Hope E Uronis; Gerard C Blobe; S David Hsu; S Yousuf Zafar; Herbert I Hurwitz
Journal:  Invest New Drugs       Date:  2013-11-01       Impact factor: 3.850

3.  NMT1 (N-myristoyltransferase 1).

Authors:  Ponniah Selvakumar; Sujeet Kumar; Jonathan R Dimmock; Rajendra K Sharma
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2011-01-07

Review 4.  The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.

Authors:  Christopher Lieu; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2010-04       Impact factor: 4.481

5.  The expression of c-src gene in the carcinogenesis process of human cardia adenocarcinoma.

Authors:  Xiu-Jie Wang; Shu-Lan Yuan; Lin Xiao; Xu-Hua Wang; Chao-Jun Wang
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

6.  ZBP1 enhances cell polarity and reduces chemotaxis.

Authors:  Kyle Lapidus; Jeffrey Wyckoff; Ghassan Mouneimne; Mike Lorenz; Lillian Soon; John S Condeelis; Robert H Singer
Journal:  J Cell Sci       Date:  2007-09-15       Impact factor: 5.285

7.  Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.

Authors:  Bart M Maślikowski; Benjamin D Néel; Ying Wu; Lizhen Wang; Natalie A Rodrigues; Germain Gillet; Pierre-André Bédard
Journal:  BMC Cancer       Date:  2010-02-12       Impact factor: 4.430

8.  Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Authors:  Scott Kopetz; Donald P Lesslie; Nikolas A Dallas; Serk I Park; Marjorie Johnson; Nila U Parikh; Michael P Kim; James L Abbruzzese; Lee M Ellis; Joya Chandra; Gary E Gallick
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

9.  Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.

Authors:  Christine M Parseghian; Nila U Parikh; Ji Yuan Wu; Zhi-Qin Jiang; Laura Henderson; Feng Tian; Brice Pastor; Marc Ychou; Kanwal Raghav; Arvind Dasari; David R Fogelman; Anastasia D Katsiampoura; David G Menter; Robert A Wolff; Cathy Eng; Michael J Overman; Alain R Thierry; Gary E Gallick; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2017-03-09       Impact factor: 12.531

10.  SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling.

Authors:  M A Westhoff; B Serrels; V J Fincham; M C Frame; N O Carragher
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.